Stoke Therapeutics (NASDAQ:STOK) Given “Sell (D+)” Rating at Weiss Ratings

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “sell (d+)” rating reiterated by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other research firms have also commented on STOK. Jefferies Financial Group initiated coverage on Stoke Therapeutics in a research note on Friday, July 18th. They set a “buy” rating and a $30.00 price objective on the stock. BTIG Research set a $28.00 price objective on Stoke Therapeutics and gave the company a “buy” rating in a research note on Monday, August 18th. Wedbush increased their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, August 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Finally, Chardan Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $25.57.

Stoke Therapeutics Stock Up 11.7%

Shares of STOK stock opened at $30.50 on Wednesday. The stock has a market cap of $1.67 billion, a P/E ratio of 35.88 and a beta of 1.24. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $32.40. The business has a fifty day simple moving average of $20.29 and a 200-day simple moving average of $13.52.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. The business had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. On average, sell-side analysts anticipate that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Edward M. Md Kaye sold 42,461 shares of Stoke Therapeutics stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $25.09, for a total value of $1,065,346.49. Following the transaction, the director directly owned 49,124 shares of the company’s stock, valued at $1,232,521.16. The trade was a 46.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Barry Ticho sold 5,501 shares of Stoke Therapeutics stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total value of $109,304.87. Following the completion of the transaction, the insider directly owned 18,469 shares in the company, valued at $366,979.03. This represents a 22.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 160,180 shares of company stock valued at $3,379,406. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock valued at $36,000 after purchasing an additional 5,084 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares in the last quarter. AlphaQuest LLC acquired a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $72,000. Finally, US Bancorp DE lifted its stake in shares of Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after purchasing an additional 11,108 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.